INOVIO PHARMACEUTICALS, INC.

INOSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1055726

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$217.8K	$832.0K	$1.8M	$7.4M	$4.1M
Research and Development Expense	$75.6M	$86.7M	$249.2M	$94.2M	$88.0M
Operating Expenses	$112.6M	$144.8M	$303.0M	$131.5M	$115.2M
Operating Income (Loss)	-$112.4M	-$143.9M	-$301.2M	-$124.1M	-$111.1M
Interest Expense	—	—	$1.9M	$8.7M	$7.9M
Other Nonoperating Income (Expense)	-$3.2M	-$4.7M	$343.4K	-$704.9K	$496.2K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$107.3M	-$135.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$113.2M	$171.0M	$348.5M	$495.9M	$539.8M
Assets, Current	$97.8M	$153.1M	$315.2M	$448.4M	$471.2M
Cash and Cash Equivalents, at Carrying Value	$65.8M	$14.3M	$46.3M	$71.1M	$250.7M
Accounts Receivable, after Allowance for Credit Loss, Current	$1.2M	$2.4M	—	$5.5M	$18.6M
Liabilities	$44.7M	$53.6M	$126.2M	$96.3M	$78.6M
Liabilities, Current	$35.3M	$42.6M	$96.9M	$65.7M	$41.7M
Stockholders' Equity Attributable to Parent	$117.3M	$222.4M	$461.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$104.1M	-$124.4M	-$215.7M	-$178.0M	-$97.9M
Net Cash Provided by (Used in) Investing Activities	$104.1M	$87.4M	-$175.3M	-$58.8M	-$9.0M
Net Cash Provided by (Used in) Financing Activities	$51.5M	$5.0M	$211.5M	$465.3M	$105.4M
Payments to Acquire Property, Plant, and Equipment	$487.8K	$320.9K	$1.2M	$1.5M	$987.9K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)